President Donald Trump has signed a memorandum instructing the Department of Health and Human Services and the Food and Drug Administration (FDA) to toughen oversight of direct-to-consumer prescription drug ads.
The order calls for stricter enforcement of disclosure rules, requiring companies to provide clearer information about side effects and risks alongside claims of effectiveness. The directive also targets newer advertising channels, including social media, influencer marketing, and online pharmacies, where regulators say misleading content has flourished.
The FDA will begin a large enforcement campaign in response, sending warning letters and cease-and-desist orders to pharmaceutical companies and ad agencies that fail to comply. Officials noted that enforcement activity had nearly disappeared in recent years, with only one warning letter issued in 2023 and none in 2024.
The administration argues that the crackdown is necessary to protect consumers from ads that exaggerate drug benefits while downplaying potential harm, restoring accountability in a multibillion-dollar industry.
